Press release
Nantes (France), November 27, 2023

#cancer #treatment #XON7 #XENOTHERA

XENOTHERA RECRUITS THE FIRST PATIENT IN THE CLINICAL TRIAL OF XON7, ITS NEW ANTI-CANCER TREATMENT

XON7 immunotherapy could be a new therapeutic approach in solid tumors.

XENOTHERA, a Nantes-based biotech developing innovative treatments using multispecific polyclonal glyco-humanized antibodies (GH-pAb), announces the enrolment of the first patient in its clinical trial in solid cancers entitled "First In class Polyclonal in Oncology" (FIPO trial, EU Trial Number 2023-505266-29-00). This Phase I/II trial is being carried out in collaboration with four hospitals, three in France and one in Belgium.

XENOTHERA's antibody platform enables accelerated development thanks to its in-house biomanufacturing facility, its clinical experience (400 patients exposed to GH-pAb), and its clinical and regulatory expertise. In less than 4 years, the French biotech has developed a new hope for patients with solid tumors. XON7 is a GH-pAb developed in several tumors, in particular lung, breast, prostate, colon and pancreas, for the most common. XON7 is an anti-cancer agent with totally innovative mechanisms of action, combining the effects of tumor destruction (oncolysis), modification of the microenvironment and synergy with immune checkpoint inhibitors. XON7 has demonstrated very significant anti-tumor effects in pre-clinical studies, and its safety in regulatory studies has enabled the European authorities to confirm its potential interest for patients.

The FIPO trial is a Phase I/II trial beginning with an ascending phase, in which increasing doses of XON7 will be administered to volunteer patients, with the aim of analyzing its safety and identifying the therapeutic dose. An expansion phase in 7 tumor indications is planned at the end of the ascending phase. FIPO has been granted a clinical trial authorization by the European Medicines Agency in September 2023. The clinical centers participating in the FIPO trial are Foch (Suresnes, France), Léon Bérard (Lyon, France), Oncopole (Toulouse, France) and Jules Bordet (Brussels, Belgium). The first patient was recruited at Hôpital Foch, in Professor Bennouna's department. XON7 was administered on November 21st, with no immediate side effects. The next patients should be recruited in the coming weeks.

"We've known for four years that our antibodies could be of interest for cancer patients. Being multi-specific and similar to natural immunity, our GH-pAb are particularly interesting, at a time when we need to push back the frontiers of anti-cancer treatments. XON7 is one of our candidates, it targets several original tumoral antigens and could be effective in many cancers with high medical needs. I would like to thank the team of the Foch hospital, the patients taking part in the trial and the hospitals involved, and I hope that the treatment will rapidly demonstrate its safety and efficacy," comments Odile Duvaux, President and co-founder of XENOTHERA.

***************
About XON7:
XON7 is a multi-specific GH-pAb from XENOTHERA’s technology platform. It targets several tumor antigens and acts through a combination of different mechanisms of action, in particular apoptosis, complement-dependent cytotoxicity and antibody-dependent phagocytosis. XON7’s ability to recognize multiple solid tumors and act synergistically with immune checkpoint inhibitors (ICIs) confirms its status as a promising candidate for a new line of treatments for several cancers affecting millions of patients. Based on fundamentally innovative and different mechanisms of action, XON7 presents itself as “first in class”, and limits the risk of tumor escape unfortunately observed with some other treatments. The FIPO first-in-human trial testing XON7 has been authorized in September 2023.

About XENOTHERA:
Founded in 2014 by a team of renowned scientists and under the presidency of Odile Duvaux, PhD and graduate of the École Normale Supérieure, XENOTHERA is a biotechnology company based in Nantes (France) that develops new therapeutic approaches in a wide range of indications, with a focus on oncology and immunology. The company develops treatments based on a unique multi-specific glyco-humanized antibody technology. Its technological platform is based on dual expertise in genetics and immunology. The biotech has a comprehensive portfolio of products, four of which have already been introduced in the clinic. Its main assets are LIS1, in onco-hematology and transplantation, and XON7, in solid tumors. XENOTHERA is part of the scientific and medical environment of the Pays de la Loire region (France). Since its creation, the company has raised 43 million euros, its main financiers being the Pays de la Loire Region, BPI France and the European fund EIC Fund, as well as private investors. More information: www.xenothera.com
Follow XENOTHERA on social networks: LinkedIn ; X

Media relations:
IZsoGOOD
Ingrid Zémor
+33 (0)6 73 72 99 92
xenothera@izsogood.co